Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Intensity Therapeutics Reports Early Radiological And Pathological Results With INT230 6 Demonstrating High Drug Absorption Tumor Necrosis And Evidence Of Immune Activation

Author: Benzinga Newsdesk | September 10, 2025 06:49am

A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the standard of care immunochemotherapy ("SOC")
Safety looks favorable in Cohort A
Some INT230-6 patients begin to show localized skin irritation, and new patient enrollment has been paused to implement modifications to resolve the issue
Patients being treated with INT230-6 continue to show significant necrosis after two doses of INT230-6 and prior to the initiation of the SOC, as shown in the photos below of a single patient's breast tumor scans

Posted In: INTS